Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
62
resultados
Última actualización
30/11/2025 [06:45:00]
Resumen de: AU2024258228A1
Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
Resumen de: WO2025242013A1
Disclosed in the present invention are a tricyclic BCL6 degradation agent and the use thereof. The tricyclic compound provided by the present invention or a pharmaceutically acceptable salt and solvate thereof has a novel structure and exhibits an excellent degradation effect on BCL6 protein. Therefore, the compound provided by the present invention or a composition containing the compound provided by the present invention exhibits a promising potential for development as drugs for treating diseases that can be treated or relieved by means of degrading the BCL6 protein, e.g., cancers such as Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, NK/T cell non-Hodgkin lymphoma, or diffuse large B-cell lymphoma.
Resumen de: US2025361227A1
The invention relates to inhibitors of EWS-FLI1, pharmaceutical compositions containing the inhibitors, and methods of treating cancer, including Ewing sarcoma, leukemia, diffuse large B-cell lymphoma (DLBCL), and prostate cancer, comprising the administration of the inhibitors and pharmaceutical compositions thereof.
Resumen de: WO2025245434A1
Aspects of the disclosure provides composition and methods for treating a subject having MDS, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Resumen de: WO2025243241A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a novel dosing schedule.
Resumen de: WO2025242909A1
The present invention relates to an antibody-radionuclide conjugate comprising a) an antibody or antigen-binding fragment thereof specifically binding to CD30; and b) terbium-161, as well as to a pharmaceutical composition comprising the conjugate of the invention as well as at least one pharmaceutically acceptable carrier. The present invention further relates to a kit of parts comprising a) an antibody or antigen-binding fragment thereof specifically binding to CD30; and b) terbium-161, wherein said antibody or antigen-binding fragment thereof is capable of binding terbium-161. The present invention further encompasses therapeutic uses of the provided conjugates. Accordingly, the antibody-radionuclide conjugates of the present invention are particularly useful in the treatment of cancer, in particular lymphoma.
Resumen de: WO2025244832A1
The invention provides novel aminoguanidine compounds, pharmaceutical compositions and therapeutic uses thereof for treating various types of cancer (e.g., brain cancer, breast cancer, pancreatic cancer, renal cancer, lung cancer, leukemias, and lymphomas) and neurological disorders (e.g., Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis), and related diseases and conditions.
Resumen de: WO2025242012A1
Disclosed are protein-targeting degradation chimeras and the use thereof. The protein-targeting degradation chimeras have a new chemical structure, exhibit a great degradation effect on the BCL6 protein, can be used for preparing BCL6 degrader drugs, and has the potential to be developed into a drug for treating diseases that can be treated or alleviated by means of the degradation of the BCL6 protein. The diseases that can be treated or alleviated by means of the degradation of the BCL6 protein comprise cancers such as Hodgkin lymphoma, B-cell-derived non-Hodgkin lymphoma, T-cell-derived non-Hodgkin lymphoma, NK/T-cell-derived non-Hodgkin lymphoma and diffuse large B-cell lymphoma.
Resumen de: WO2025244973A1
The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof bispecific antibodies or antigen-binding fragments thereof that bind to BCMA and CD3. In certain embodiments, the bispecific BCMAxCD3 antibodies are administered subcutaneously to the subject in need thereof. In certain embodiments, the subject has been previously treated with BCMA-CAR-T cell therapy.
Resumen de: WO2025242806A1
The present invention relates to a method for predicting a response of a patient with diffuse large B-cell lymphoma (DLBCL) to anti-IL-1β therapy. This comprises detecting a mutation in the IRF2BP2 gene and/or a lack of IRF2BP2 protein expression of the patient's DLBCL cells in a sample derived from the patient. In addition, the invention relates to the use of such detection for predicting a response of the patient to IL-1β therapy and a corresponding PCR kit.
Resumen de: US2025362298A1
Methods of monitoring progression of multiple myeloma or plasmacytoma, particularly relapsed or refractory multiple myeloma, are described. Also described are methods of treating or determining response to a treatment for multiple myeloma or plasmacytoma in a subject.
Resumen de: US2025360103A1
The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4;14) multiple myeloma, by administrating to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
Resumen de: AU2024283865A1
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
Resumen de: EP4653456A2
The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
Resumen de: EP4653445A1
Provided is compound A or a pharmaceutically acceptable salt thereof in a crystalline form. The structure of compound A is represented by formula (I) below. Studies have shown that a crystalline form A-1 of the free base of compound A, crystalline form B of a hydrochloride salt of compound A and crystalline form C of a benzenesulfonate salt of compound A have certain physical stability and chemical stability. The compound A or the pharmaceutically acceptable salt thereof in a crystalline form can significantly inhibit the proliferation of various cells of tumors such as breast cancer, colorectal cancer, ovarian cancer, melanoma, liver cancer, lung cancer and acute myeloid leukemia; and also has a good inhibitory effect on palbociclib-resistant (including primary drug resistance and acquired drug resistance) breast cancer and liver cancer. Therefore, the compound A or the pharmaceutically acceptable salt thereof in a crystalline form has good clinical application prospects in the treatment of advanced malignant tumors, and provides a new drug choice for the treatment of CDK4/6 inhibitor-resistant tumors.
Resumen de: WO2025237908A1
The present invention relates to the field of the treatment of cancer. In this study, the inventors found that VDAC2 is heterogeneously expressed in MM cells. VDAC2 protein expression correlated with BAK but not with BAX protein levels. Transient silencing of VDAC2, but not VDAC1 or VDAC3, sensitized MM cells to intrinsic mitochondrial apoptosis signals, alongside with the induction of pre-activated BAK and the increase of global, MCL1 and BCL2 mitochondrial priming. They also found a that a VDAC2 compound, efesevin recapitulated the sensitization effect of VDAC2 knock-down on BH3 mimetics apoptotic response. This novel VDAC2 modulator sensitized MM cells to BH3 mimetics targeting MCL1 (S63845) or BCL2 (Venetoclax) without modifying BAK or BAX protein expression. The efficiency of the VDAC2 modulator was directly correlated with the levels of VDAC2 protein. To better understand the VDAC2/BAK interplay, The inventors generated VDAC2 KO myeloma cells. VDAC2 KO cells exhibited an important decrease of BAK protein expression while BAX remained unchanged. Accordingly, VDAC2 KO cells completely lost their mitochondrial priming. Interestingly, they also found that BAK KO myeloma cells displayed decreased levels of VDAC2. The reciprocal regulation between VDAC2 and BAK was dependent on both the proteasome and lysosome degradation pathways. Thus, the present invention relates to a combination of a VDAC2 modulator and a BH3- mimetics compound for use in the treatment of a cancer in a s
Resumen de: AU2024261833A1
Provided herein are methods comprising multifunctional binding proteins comprising a first and a second antigen binding domain and all or part of an immunoglobulin Fc region or variant thereof, wherein the first antigen binding domain binds specifically to CD123 and the second antigen binding domain binds specifically to human NKp46, and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor, for the treatment or prevention of leukemias and myelodysplastic disorders.
Resumen de: AU2024243824A1
The present disclosure relates to combination dosing regimen comprising an anti-KMA antibody, an IMiD/CELMoD and a steroid. Such combinations may be used for the treatment of multiple myeloma.
Resumen de: WO2025240852A1
In one aspect, the disclosure relates to composition and methods for proteolysis-targeting chimeric molecules (PROTACs). In some aspects, the disclosed compounds are useful for modulating LCK tyrosine kinase activity through targeted degradation. In some aspects, the disclosed compounds are orally bioavailable. In further aspects, the present disclosure relates to methods of making the disclosed compounds, pharmaceutical compositions comprising the disclosed compounds, and methods of treating various clinical conditions and disorders using the same, such as T-cell acute lymphoblastic leukemia. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
Resumen de: WO2025236094A1
Identification, Design and Validation of Public Neoantigens and Tumor-associated Antigen vaccines for the Prevention and Treatment of Down Syndrome-associated Leukemia.
Resumen de: US2025352582A1
The present invention includes compositions and methods for treating AML utilizing bispecific CARs. In certain aspects, the invention includes a bispecific split CAR which binds CD13 and TIM-3 on AML cells.
Resumen de: US2025354218A1
The present technology relates to methods for predicting the risk of acute myeloid leukemia (AML) in a subject prior to the onset of AML symptoms, and whether such a subject will benefit from treatment with an AML therapy. The methods disclosed herein are based on detecting the presence of mutations in the nucleic acid sequences of IDH1/2, TP53, DNMT3A, TET2, and spliceosome genes. Kits for use in practicing the methods are also provided.
Resumen de: US2025353854A1
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds described herein. Methods of using the menin or menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin or menin-MLL interaction.
Resumen de: AU2025259861A1
The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. Arsenic treatment has shown great promise in the treatment of several cancers but requires daily intravenous (IV) administration. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. As a result, the formulation facilitates a systemic bioavailability comparable to that of intravenous (IV) administration of arsenic trioxide currently practiced. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation. The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid
Nº publicación: AU2025259981A1 20/11/2025
Solicitante:
ARGENX BVBA
UNIV OF BERN
argenx BVBA,
University of Bern
Resumen de: AU2025259981A1
The invention relates to combination therapies, particularly combination therapies for the treatment of myeloid malignancy. The combination therapies are particularly useful in methods for the treatment of acute myeloid leukemia (AML). The combination therapies 5 include an antibody or antigen binding fragment thereof that binds to CD70 and a BCL-2 inhibitor, preferably venetoclax or a pharmaceutically acceptable salt thereof. 10 15 20 25 The invention relates to combination therapies, particularly combination therapies for the treatment of myeloid malignancy. The combination therapies are particularly useful in 5 methods for the treatment of acute myeloid leukemia (AML). The combination therapies include an antibody or antigen binding fragment thereof that binds to CD70 and a BCL-2 inhibitor, preferably venetoclax or a pharmaceutically acceptable salt thereof. ct c t
BOPI
Sede Electrónica
